Effects of purified fish oil-containing dietary supplement on serum triglycerides, blood pressure, and cognitive function in healthy Japanese middle-agers - Randomized, double-blind, placebo-controlled parallel-group trial

Japanese Pharmacology and Therapeutics

Volumn 44, Issue 2, 2016, Pages 235-246

  Matsumoto, Yoshiyuki ^a   Matsunaga, Hirohide ^a   Nishimura, Tomoka ^a   Ryuno, Yoshikazu ^a   Akaoka, Kazushi ^a   Matsumoto, Yusaku ^a   Seto, Kayoko ^a   Kitano, Tadao ^a   Kondo, Sumio ^b   Nishikawa, Masazurai ^c  

^a Department of Research and Development Egao Co Ltd   (Japan)

^b Medical Corporation Kenshokai Fukushima Healthcare Center   (Japan)

^c MIYAGI UNIVERSITY   (Japan)

Author keywords

Blood pressure; Cognitive function; Fish oil; Japanese middle ager; Serum triglycerides

Indexed keywords

EID: 84964461782     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengaill/
2. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115:450-8.
3. Le NA, Walter MF. The role of hypertriglyceridemia in atherosclerosis. Curr Atheroscler Rep 2007; 9: 110-5.
4. Jacobson TA, Miller M, Shaefer EJ. Hypertriglyceridemia and cardiovascular rsk reduction. Clin Ther 2007; 29: 763-77.
5. Bersot T, Haffner S, Harris WS, Kellick KA, Morris CM. Hypertriglyceridemia: management of atherogenic dyslipidemia. J Fam Pract 2006; 55: S1-8.
6. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
7. Hyson D, Rutledge JC, Berglund L. Postprandial lipemia and cardiovascular disease. Curr Atheroscler Rep 2003; 5: 433-8.
8. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, et al.; Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004; 110: 2678-86.
9. Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Ono Y, Nishimura K, et al. A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13-year cohort study of Japanese: the Suita study. Atherosclerosis 2011; 217: 201-6.
10. Satoh H, Nishino T, Tomita K, Tsutsui H. Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men. Circ J 2006; 70: 227-31.
11. Saito I, Folsom AR, Aono H, Ozawa H, Ikebe T, Yamashita T. Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA. Int J Epidemiol 2000; 29: 837-44.
12. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 2011; 13: 474-83.
13. Musa-Veroso K, Binns MA, Kocenas AC, Poon T, Elliot JA, Rice H, et al. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. Nutr Rev 2010; 68: 155-67.
14. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006; 189:19-30.
15. Lewis A, Lookinland S, Beckstrand RL, Tiedeman ME. Treatment of hypertriglyceridemia with omega-3 fatty acids: a systematic review. J Am Acad Nurse Pract 2004; 16: 384-96.
16. Weber P, Raederstorff D. Triglyceride-loweing effect of omega-3 LC-polyunsaturated fatty acids-a review. Nutr Metab Cardiovasc Dis 2000; 10: 28-37.
17. Mazaffarian D, Wu JH. (n-3) Fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr 2012; 142: 614S-25S.
18. Hill AM, Buckley JD, Murphy KJ, Howe PRC Combining fish oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. Am J Clin Nutr 2007; 85: 1267-74.
19. Breslow JL n-3 Fatty acids and cardiovascular disease. Am J Clin Nutr 2006; 83 (suppl): 1477S-82S.
20. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-57.
21. Mori TA, Beilin LJ. Long-chain omega-3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 2001; 12:11-7.
22. Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006; 9: 95-104.
23. Appel LJ, Miller ER III, Seidler AJ, Whelton PK. Does supplementation of diet with 'fish oil' reduce blood pressure? Arch Intern Med 1993; 153: 1429-38.
24. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? a meta-analysis of controlled trials. Circulation 1993; 88: 523-33.
25. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 1997; 145: 33-41.
26. Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 2004; 62: 275-80.
27. Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S, Lodi L. Cognitive and physiological effects of omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur J Clin Invest 2005; 35: 691-9.
28. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007; 85: 1142-7.
29. Terano T, Fujishiro S, Ban T, Yamamoto K, Tanaka T, Noguchi Y, et al. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids 1999; 34 (Suppl): S345-6.
30. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, et al. ω-3 Fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: Omega AD Study. A randomized double-blind trial. Arch Neurol 2006; 63: 1402-8.
31. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimers disease. Arch Neurol 2003; 60: 940-6.
32. Houx PJ, Vreeling FW, Jolles J. Stroop interference: aging effects assessed with the Stroop Color-Word Test. Aging Res 1993; 19: 209-24. http://www.mhlw.go.jp/stf/houdou/2r9852000002qlst.html
33. Harris WS: n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65 (suppl): 1645S-54S.
34. Burns T, Maciejewski SR, Hamilton WR, Zheng M, Moos AN, Hilleman DE. Effect of omega-3 fatty acid supplementation on the arachidonic acid: eicosapentaenoic acid ratio. Pharmacotherapy 2007; 27: 633-8.
35. Hirai A, Hamazaki T, Terano T, Nishikawa T, Tamura Y, Kamugai A, et al. Eicosapentaenoic acid and platelet function in Japanese. Lancet 1980; 2: 1132-3.
36. Lungershausen YK, Abbey M, Nestel PJ, Howe PR. Reduction of blood pressure and plasma triglycerides by omega-3 fatty acids in treated hypertensives. J Hypertens 1994; 12: 1041-5.
37. Davidson MH, Maki KC, Kalkowski J, Schaefer EJ, Torri SA, Drennan KB. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr 1997; 16: 236-43.
38. Pownall HJ, Brauchi D, Kilinc C, Osmundsen K, Pao Q, Payton-Ross C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999; 143: 285-97.
39. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al.; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hyperglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29: 1354-67.
40. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications. Exp Rev Cardiovasc Ther 2008; 6: 391-409.
41. Russo C, Olivieri O, Girelli D, Azzini M, Stanzial AM, Guarini P, et al. Omega-3 polyunsatruated fatty acid supplements and ambulatory blood pressure monitoring parameters in patients with mild essential hypertension. J Hypertens 1995; 13: 1823-6.
42. Prisco D, Paniccia R, Bandinelli B, Filippini M, Francalanci I, Giusti B, et al. Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res 1998; 91: 105-12.
43. Miyajima T, Tsujino T, Saito K, Yokoyama M. Effects of eicosapentaenoic acid on blood pressure, cell membrane fatty acids, and intracellular sodium concentration in essential hypertension. Hypertens Res 2001; 24: 532-42.
44. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20: 1493-9.
45. Barberger-Gateau P, Letenneur L, Dechamps V, Peres K, Dartigues JF, Renaud S. Fish, meat, and risk of dementia: cohort study. BMJ 2002; 325: 932-3.
46. Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005; 65: 1409-14.
47. Barberger-Gateau P, Jutand MA, Letenneur L, Larrieu S, Tavernier B, Berr C. Correlates of regular fish consumption in French elderly community dwellers: data from the Three-City study. Eur J Clin Nutr 2005; 59: 817-25.
48. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimers disease, other types of dementia, and cognitive impairment. Lipids 2000; 35: 1305-12.
49. Alessandri JM, Guesnet P, Vancassel S, Astorg P, Denis I, Langelier B, et al. Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod Nutr Dev 2004; 44: 509-38.